Professor Wayne Tilley, PhD

Also check this link to the University Staff Directory as it may contain a more updated profile of this staff member including expertise and contact details.

Staff
A/Prof David Horsfall, Senior Research Fellow
Dr Steve Birrell, Senior Visiting Surgeon
Dr Lisa Butler, RAH IMVS Florey Research Fellow
Dr Grant Buchanan, NHMRC CJ Martin Research Fellow
Dr Carmela Ricciardelli, University of Adelailde Research Fellow
Dr Tina Bianco-Miotto, NHMRC Peter Doherty Research Fellow
Dr Theresa Hickey, NHMRC Peter Doherty Research Fellow
Dr Andrew Sakko, W Bruce Hall Cancer Research Fellow
Dr Jeffrey Barrett, Grant Funded Scientist
Laura Almeroth, Personal Assistant to Prof Tilley
Katrina Ramsay, Grants and Publications Manager
Helen Hughes, Research Nurse
Catherine Calan, Clinical Trial Coordinator
Marie Pickering, Research Assistant
Miriam Butler, Research Assistant
Michelle Newman, Research Assistant
Ean Phing Lee, Research Assistant
Sook Ching Lee, Research Assistant
Kai Mak, Research Assistant
Margaret Yard, Technical Assistant

Higher Degree students
Sarah Carter
Margaret Centenera
HuiQin (Karen) Chiam
Elisa Cops
Eleanor Need
Aleksandra Ochnik
Amelia Peters

Current Funded Research
2004 –2009 NHMRC Grant. Enabling Grant: Australian Prostate Cancer Collaboration (APCC) BioResource.  $420,000 pa

2005-2007 NHMRC Grant. Prognostic importance of androgen receptors in epithelium and    stroma in early stage prostate cancer.   $114,300 pa

2005-2008 The Susan G Komen Breast Cancer Foundation (USA) Grant. The role of androgen receptor signalling in the breast: potential disruption by synthetic progestins used in hormone replacement therapy.  $USD83,333 pa

2006-2008 US Army Medical Research and Material Command Congressionally Directed Medical Research Programs Grant. Disruption of the circadian rhythms of gene expression and the development of breast.  $130,530 pa

2006-2008 The Susan G Komen Breast Cancer Foundation (USA) Grant. Androgen receptor status as a determinant of breast cancer risk and disease progression.  US$77,963 pa

2007 ARC LIEF Grant. A microarray platform for gene expression. $196,000

2007 NHMRC Grant. Equipment Grant – Automated Image Analysis System.  $100,695 (+ $25,000 from Faculty Health Science)

2007-2009 NHMRC Grant. Androgen receptor signalling in development and progression of prostate cancer.  $241,250 pa

2007-2009 NHMRC Grant. Androgen receptor activity in normal and abnormal human ovarian function.  $133,375 pa

2007-2009 National Breast Cancer Foundation Grant. Androgen receptor status as a determinant of breast cancer risk. $84,668 pa

2007-2010 US Army Medical Research and Material Command Congressionally Directed Medical Research Programs Grant. Mechanism of Prostate Cancer Tumorigenesis. USD$160,340 pa

Most recent publications
Birrell SN, Butler LM, Harris JM, Buchanan G and Tilley WD. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. (In press,Apr 5, 2007, Epub ahead of print.). [Impact factor 6.721]

Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 16: 763-8; 2007. [Impact factor 4.289]

Reichardt JK, Tilley WD. The 3rd Pacific Rim meeting on breast and prostate cancer: progress in hormonal carcinogenesis and the enduring influence of Ron Ross. Cancer Res. 67: 4550-2; 2007. [Impact factor 7.656]

Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, Arasheben A, Tilley WD, Scher HI, Gerald WL, Buchanan G, Coetzee GA, Frenkel B. Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer. 6 : 39; 2007.

Ricciardelli C, Russell DL, Ween MP, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ. Formation of hyaluronan-and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem. 282: 10814-25; 2007. [Impact factor 5.808]

Robzyk K, Oen H, Mandal A, Buchanan G, Butler LM, Tilley WD, Mandal AK, Rosen N and Caplan AJ. Uncoupling of Hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Mol Cell Endocrinol. 268: 67-74, 2007. [Impact factor 2.918]

Dwivedi PP, Anderson PH, Tilley WD, May BK, Morris HA. Role of oncoprotein Growth Factor Independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): A comparative analysis in human prostate cancer and kidney cells. J Steroid Biochem Mol Biol. 103: 742-6, 2007. [Impact factor 2.825]

Hayes VM, Severi G, Padilla EJD, Morris HA, Tilley WD, Southey MC, English DR, Sutherland RL, Hopper JL, Boyle P and Giles GG. Complexity of 5-alpha reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer. 120: 776-80; 2007. [Impact factor 4.693]

Sakko AJ, Ricciardelli, Mayne K, Dours-Zimmermann MT, Zimmermann DR, Neufing P, Tilley W, Marshall VR and Horsfall DJ. Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormonal manipulation. Prostate. 67: 288-300; 2007. [Impact factor 3.724]

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM and Butler LM. Suberoylanilide hydroxamic acid (SAHA; vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 51-60; 2007. [Impact factor 5.137]

Chmelar R, Buchanan G, Need EF, Tilley WD and Greenberg, NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719-733, 2006. [Impact factor 4.693]

Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thaile M, Labrinidis A, Tilley WD, Findlay DM and Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer.119: 944-54, 2006. [Impact factor 4.693; Cited 1]

Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P and Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 86-91, 2006. [Impact factor 4.289; Cited 7]

Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P and Giles GG. Circulating insulin-like growth factor-1 and binding protein-3 and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev.15: 1142-7, 2006. [Impact factor 4.289; Cited 1]

Severi G, Hayes VM, Neufing P, Padilla EJD, Tilley W, Eggleton SA, Morris H, English DR, Southey M, Hopper JL, Sutherland RL, Boyle P and Giles GG. Variants in the Prostate-Specific Antigen (PSA) gene and prostate cancer risk, survival and circulating PSA. Cancer Epidemiol Biomarkers Prev.15: 1142-7, 2006. [Impact factor 4.289]

Zeng G, Day TK, Hooker AM, Blyth BJ, Bhat M, Tilley WD and Sykes PJ. Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutat Res 602: 65-73, 2006. [Impact factor 4.111 ]

Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M, Brown MP and Tilley WD. Inhibitory receptor variants suppress androgen receptor signaling in prostate cancer cells. Mol Endocrinol 20: 1009-1024, 2006. [Impact factor 4.967]

Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM and Tilley WD. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 65: 8487-8496, 2005. [Impact factor 7.656; Cited 5]

Beekman KW, Buchanan G, Tilley WD and Scher HI. Beyond first line hormones: options for castration-resistant disease. In: Vogelzang NJ, Scardina PT, Shipley WU, Coffey D (Eds). Comprehensive Textbook of Genitourinary Oncology (Third Edition). Wiley and Williams, Lippincott, Philadelphia, pp. 330-340, 2005.

Beekman KW, Buchanan G, Tilley WD and Scher HI. Anti-Androgen Withdrawal Syndromes: Pathophysiology and Clinical Implications. Partin AW (Ed). Prostate Cancer: Principles and Practice. London, Taylor and Francis, 2005.

Makridakis NM, Buchanan G, Tilley WD and Reichardt JK. Androgen metabolic genes in prostate cancer predisposition and progression. Frontiers in Bioscience 10: 2892-2903, 2005. [Impact factor 2.771; Cited 1]

Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ and Tilley WD. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 63: 19-28, 2005. [Impact factor 3.724; Cited 7]

Han G, Buchanan G, Harris JM, Ittmann M, Yu X, DeMayo FJ, Tilley WD and Greenberg NM. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102: 1151-1156, 2005. [Impact factor 9.643; Cited 32]

Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD and Coetzee GA. GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem 386: 69-74, 2005. [Impact factor 2.752; Cited 2]

Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma V, LeBaron RG, Raymond WA, Tilley WD and Horsfall DJ. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498, 2004. [Impact factor 6.177; Cited 9]

Scher HI, Buchanan G, Gerald W, Butler LM, and Tilley WD. Targeting the androgen receptor: improving outcomes for castration resistant prostate cancer. Endocr Relat Cancer 11: 459-476, 2004. [Impact factor 4.763; Cited 25]

Jia L, Choong C, Ricciardelli C, Tilley WD and Coetzee GA. Androgen receptor signaling: mechanism of IL-6 inhibition. Cancer Res 64: 2619-2626, 2004. [Impact factor 7.656; Cited 23]

Hooker AM, Morley AA, Tilley WD and Sykes PJ. Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. Mutat Res 550: 1-10, 2004. [Impact factor4.111; Cited 3]  

Hollington P, Neufing P, Kalionis B, Waring P, Bentel J, Wattchow D and Tilley WD. Expression and localisation of homeodomain proteins DLX4, HB9 and HB24 in malignant and benign human colorectal tissues. AntiCancer Res 24: 955-962, 2004. [Impact factor 1.479; Cited 4]

Hall RE, Horsfall DJ, Stahl J, Vivekanandan S, Ricciardelli C, Stapleton AMF, Scardino PT, Neufing P and Tilley WD. Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer. Prostate 58: 103-108, 2004. [Impact factor 3.724; Cited 3]

Buchanan G, Yang M, Cheong A, Harris J, Irvine R, Lambert P, Moore N, Raynor M, Neufing P, Coetzee G and Tilley WD. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13: 1677-1692, 2004. [Impact factor 8.099; Cited 22]

Buchanan G, Craft PS, Yang M, Cheong A, Prescott J, Jia L, Coetzee GA and Tilley WD. PC-3 cells with enhanced androgen receptor signalling: a model for clonal selection in prostate cancer. Prostate 60: 352-366, 2004. [Impact factor 3.724; Cited 5]

Zhang L, Brereton HM, Hahn M, Froscio M, Tilley WD, Brown MP and Barritt GJ. Expression of the Drosophila transient receptor potential-like (TRPL) Ca2+ channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Ther 10: 611-625, 2003. [Impact factor 4.187; Cited 3]

Severi G, Giles GG, Southey MC, Tesoriero A, Tilley WD, Neufing P, Morris H, English DR, McCredie MRE, Boyle P and Hopper JL. ELAC2/HPC2 polymorphisms are not associated with prostate cancer or serum prostate-specific antigen level. J Natl Cancer Inst 95: 818-824, 2003. [Impact factor 15.271; Cited 20]

Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR, Tilley WD and Horsfall DJ. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 63: 4786-4791, 2003. [Impact factor 7.656; Cited 15]

Tilley WD, Buchanan G and Coetzee GA. Hormones and cancer. Androgen receptor signaling in prostate cancer. In: Hormones, Genes, and Cancer (Eds. Henderson BE, Ponder B and Ross RK), Oxford University Press, New York; pp. 288-315, 2003. [Cited 5]

Neufing PJ, Kalionis B, Vivekanandan S, Ricciardelli C, Raymond W, Horsfall DJ, and Tilley WD. Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant breast tissues. AntiCancer Res 23: 1479-1488, 2003. [Impact factor 1.479; Cited 03]

Kim J , Jia L, Tilley WD and Coetzee GA. Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucl Acids Res 31: 6741-6747, 2003. [Impact factor 6.317; Cited 15]

Jia L, Kim J, Shen H, Clark PE, Tilley WD and Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: Steroidal and non-steroidal mechanisms. Mol Cancer Res 1: 385-392, 2003. [Impact factor 4.759; Cited 22]

Jackson MJ Roberts JS, Heckford SE, Ricciardelli C, Choong C, Stahl J, Horsfall DH and Tilley WD. Potential autocrine regulation of prostate tumour growth by vascular endothelial growth factor (VEGF). Cancer Res 62: 854-859, 2002. [Impact factor 7.656; Cited 70]

Alaina J, James IUA, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ and Weigel NL. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol 16: 2692-2705, 2002. [Impact factor 4.967; Cited 8]

Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20: 207-223, 2001. [[Impact factor 6.115; Cited 45]

Buchanan G, Greenberg NM, Sher HI, Harris JM, Marshall VR and Tilley WD. Co-location of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7: 1273-1281, 2001. [Impact factor 6.177; Cited 61]

Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD and Greenberg NM. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activites in autochthonous prostate cancer. J Biol Chem 276: 11204-11213, 2001. [Impact factor 5.808; Cited 55]

Buchanan G, Yang M, Harris J, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM and Tilley WD. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15: 46-56, 2001. [Impact factor 4.967; Cited 43]

Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, LeBaron RG and Horsfall DJ. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell derived TGFb. Cancer Res 61: 926-930, 2001. [Impact factor 7.656; Cited 30]

Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF and Coetzee GA. BRCA1 potentiates androgen receptor signaling in breast and prostate cells. Cancer Res 60: 5946-5949, 2000. [Impact factor 7.656; Cited 69]

Buchanan G and Tilley W. Androgen Receptor Structure and Function in Prostate Cancer. In: Hormonal Carcinogenesis III (Eds. Li, J.J., J.R. Daling, S.A. Li), Springer-Verlag, New York, pp. 333-341, 2000.

Bentel JM, Pickering MA, Pollard M, Clements JA and Tilley WD. Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines. In Vitro Cell Dev Biol 35: 655-62, 1999. [Impact factor 0.735]

Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD and Horsfall DJ. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early stage prostate cancer. Cancer Res 59: 2324-2328, 1999. [Impact factor 7.656; Cited 17]

Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ and Tilley WD. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 154: 11-20, 1999. [Impact factor 2.918; Cited 47]

Clements JA, Rohde P, Allen V, Hyland VJ, Hema Samaratunga MLT, Tilley WD, Lavin MF and Gardiner RA. Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. J Urol 161: 1-7, 1999. [Impact factor 3.956; Cited 15]

Birrell SN, Hall RE and Tilley WD. Role of the androgen receptor in human breast cancer. J Mamm Gland Biol Neoplasia 3: 95-103, 1998. [Impact factor 3.800; Cited 35]

Hall RE, Clements JA, Birrell SN and Tilley WD. Prostate specific antigen and gross cystic disease fluid protein-15 are coexpressed in androgen receptor positve breast tumours. Br J Cancer 78: 360-365, 1998. [Impact factor 4.459; Cited 20]

Zhang S, Bentel JM, Ricciardelli C, Horsfall DJ, Haagensen DE, Marshall VR and Tilley WD. Immunolocalization of apolipoprotein-D, androgen receptor and prostate specific antigen in early stage prostate cancers. J Urol 159: 548-554, 1998. [Impact factor 3.956; Cited 12]

Jackson MJ, Bentel JM and Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-2328, 1997. [Impact factor 3.956; Cited 90]

Ricciardelli C, Mayne K, Sykes PJ, Raymond W, Tilley WD, McCaul K, Marshall VR, Skinner JM and Horsfall DJ. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early stage prostate cancer. Clin Cancer Res: 983-992, 1997. [Impact factor 6.177; Cited 20]

Bentel JM, Buchanan G and Tilley WD. Androgen receptor gene mutations in prostate cancer. In: R Naz (Ed). Frontiers in Bioscience; Prostate: Basic and Clinical Aspects, 219-244, 1997. [Impact factor 2.771]

Bentel JM and Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 151: 1-11, 1996. [Impact factor 3.072; Cited 56]

Hall RE, Aspinall JO, Birrell SN, Horsfall DJ, Bentel JM, Sutherland RS and Tilley WD. Expression of the androgen receptor and an androgen responsive protein, apolipoprotein-D, in human breast cancer. Brit J Cancer 74: 1175-1180, 1996. [Impact factor 4.459; Cited 26]

Tilley WD, Buchanan G, Hickey TE and Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen-independence. Clin Cancer Res 2: 277-286, 1996. [Impact factor 6.176; Cited 184]

Choong CS, Sturm MJ, Strophair JS, McCulloch RK, Tilley WD, Leedman, P and Hurley DM. Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels. J Clin Endocrinol Metab 81: 236-243, 1996. [Impact factor 5.799; Cited 13]

van Wezel IL, Umapathysivam K, Tilley WD and Rodgers RJ. Immunohistochemical localization of basic fibroblast growth factor in the bovine ovary. Mol Cell Endocrinol 115: 133-140, 1995. [Impact factor 2.918; Cited 34]

Birrell SN, Bentel JM, Hickey TE, Ricciadelli C, Weger MA, Horsfall DJ and Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52: 459-467, 1995. [Impact factor 2.825; Cited 72]

Aspinall JO, Bentel JM, Haagensen DE, Horsfall DJ, Marshall VR and Tilley WD. Differential expression of two androgen regulated proteins in normal and malignant human prostate tissues. J Urol 154: 622-628, 1995. [Impact factor 3.956; Cited 24]

Birrell SN, Roder DM, Bentel JM, Horsfall DJ and Tilley WD. Medroxy-progesterone acetate therapy in advanced breast cancer; prognostic value of androgen receptor expression. J Clin Oncol 13: 1572-1577, 1995. [Impact factor 13.598; Cited 36]

Greenberg NM, DeMayo F, Finegold M, Medina D, Tilley WD, Aspinall JO, Cunha, GR, Donjacour, AA, Matusik RJ and Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443, 1995. [Impact factor 9.643; Cited 395]

Tilley WD, Bentel JM, Aspinall JO, Hall RE and Horsfall DJ. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 60: 180-186, 1995. [No Impact factor; Cited 21 ]

Horsfall DJ, Mayne K, Skinner JM, Saccone GTP, Marshall VR and Tilley WD. Glycosaminoglycans of the guinea pig prostate fibromuscular stroma during ageing and hormonal manipulation. Prostate 25: 320-332, 1994. [Impact factor 3.724; Cited 12]

Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR and Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by video image analysis. Cancer Res 54: 4096-4102, 1994. [Impact factor 7.656; Cited 66]

Hall RE, Birrell SN, Tilley WD and Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer 30A: 484-490, 1994. [Impact factor 4.167; Cited 38]

Horsfall DJ, Mayne K, Ricciardelli C, Rao M, Skinner JM, Henderson DW, Marshall VR and Tilley WD. Age-related changes in guinea pig prostatic stroma. Lab Invest 70: 753-763, 1994. [Impact factor 4.453; Cited 28]   

Ricciardelli C, Horsfall DH, Sykes PJ, Marshall VR and Tilley WD. Effects of 17-oestradiol and 5-dihydrotestosterone on guinea pig prostate smooth muscle cell proliferation and steroid receptor expression in vitro. J Endocrinol 140: 373-383, 1994. [Impact factor 3.072; Cited 15]

Lim-Tio SS, Horsfall DJ, Skinner JM and Tilley WD. Relationship of androgen receptor status to disease progression in prostate cancer. In: De Bellis A, Marsche KB Eds. New Perspectives in Endocrinology. Serono Symposia Publications, Raven Press, NY, Vol 99: 403-405, 1993. .[no impact factor]

Tilley WD, Birrell SN and Aspinall JO. Breast and prostate cancer. Recent advances in clinical and laboratory endocrinology. Fellowship Affairs 12: 25-28, 1993.[no impact factor]

Marcelli M, Tilley WD, Zoppi S., Griffin JE and Wilson JD. Molecular basis of androgen resistance. J Endocr Invest 15: 149-159, 1992.[Impact factor 1.469; Cited 16]

Hall RE, Tilley WD, McPhaul MJ and Sutherland RL. Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast cancer cells. Int J Cancer 52: 778-784, 1992. [Impact factor 4.693; Cited 36]

Tilley WD. The molecular basis of androgen resistance. Proc Aust Endocr Soc 34: 171-174, 1991.[no impact factor]

Gill PG, Tilley WD, De Young NJ, Horsfall DR, Lensink I and Dixon P. Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin and EGF. Breast Cancer Res Treat 20: 53-62, 1991. [Impact factor 4.671; Cited 9]

McPhaul MJ, Marcelli M, Tilley WD, Griffin JE and Wilson J.D. Androgen resistance caused by mutations in the androgen receptor gene. FASEB J 5: 2910-2915, 1991. [Impact factor 6.721; Cited 72]

Marcelli M, Tilley WD, Zoppi S, Griffin JE, Wilson JD and McPhaul MJ. Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg-Cys) results from a combination of decreased mRNA levels and impairment of receptor function. J Clin Endocrinol Metab 73: 318-325, 1991[Impact factor 5.799; Cited 66]

McPhaul MJ, Marcelli M, Tilley WD, Griffin JE, Isidro-Gutierrez RF and Wilson JD. Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high dose androgen therapy. J Clin Invest 87: 1413-1421, 1991. [Impact factor 15.754; Cited 104]

Tilley WD, Wilson CM, Marcelli M and McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386, 1990. [Impact factor 7.656; Cited 166]

Tilley WD, Marcelli M and McPhaul MJ. Expression of the human androgen receptor gene utilises a common promoter in diverse human tissues and cell lines. J Biol Chem 265: 13776-13781, 1990. [Impact factor 5.808; Cited 1]

Marcelli M, Tilley WD, Wilson CM, Griffin JE, Wilson JD and McPhaul MJ. Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance; premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. Mol Endocrinol 4: 1105-1116, 1990. [Impact factor 4.967; Cited 138]

Husmann DA, McPhaul MJ, Tilley WD, Wilson JD and Wilson CM. Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinol 126: 2359-2368, 1990. [Impact factor 5.236; Cited 152]

Marcelli M, Tilley WD, Wilson CM, Wilson JD, Griffin JE and McPhaul MJ. A single nucleotide substitution introduces a premature termination codon into the androgen receptor gene of a patient with receptor-negative androgen resistance. J Clin Invest 85: 1522-1528, 1990. [Impact factor 15.754; Cited 86]

Tilley WD, Marcelli M and McPhaul MJ. Recent studies of the androgen receptor: new insights to old questions. Mol Cell Endocrinol 68: C7-C10, 1990. [Impact factor 2.918; Cited 21]

Ricciardelli C, Horsfall DJ, Skinner JM, Henderson DW, Marshall VR and Tilley WD. Development and characterisation of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cell Dev Biology 25: 1016-1024, 1989. [Impact factor 0.735; Cited 28 ]

Horsfall DJ, Goldsmith KG, Ricciardelli C, Skinner. JM, Tilley WD and Marshall VR. Steroid hormone and epidermal growth factor receptors in meningiomas. Aust NZ J Surg 59: 881-888, 1989. [Cited 9]

Tilley WD, Horsfall DJ, Skinner JM, Henderson DW and Marshall VR. Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. Prostate 15: 195-210, 1989. [Impact factor 3.724; Cited 9]

Horsfall DJ, Jarvis LR, Grimbaldeston MA, Tilley WD and Orell SR. Immunocytochemical assay for oestrogen receptor in fine needle aspirates of breast cancer by video image analysis. Br J Cancer 59: 129-134, 1989. [Impact factor 4.459; Cited 17]

Cooper JA, Rohan TE, Cant EL, Horsfall DJ and Tilley WD. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer 59: 119-125, 1989 [Impact factor 4.459l; Cited 67]

Tilley WD, Marcelli M, Wilson JD and McPhaul MJ. Characterisation and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci (USA) 86: 327-331, 1989. [Impact factor 9.643; Cited 363]

Van Haaften-Day C, Raghaven D, Russell P, Wills EMJ, Gregory P, Tilley WD and Horsfall DJ. Xenografted small cell undifferentiated cancer of the prostate. Possible common origin with prostatic adenocarcinoma. Prostate 11: 271-279, 1987. [Impact factor 3.724; Cited 43]

Tilley WD, Horsfall D, McGee M, Alderman J and Marshall VR. Effects of aging and hormonal manipulations on the level of oestrogen receptors in the guinea pig prostate. J Endocrinol 112: 139-144, 1987. [Impact factor 3.724; Cited 6]

Horsfall D, Tilley WD, Orell S, Marshall VR and Cant E. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. Brit J Cancer 53: 23-28, 1986. [Impact factor 4.459; Cited 80]

Tilley WD, Horsfall D, McGee M, Henderson D and Marshall VR. Distribution of oestrogen and androgen receptors between the stroma and epithelium of the guinea pig prostate. J Steroid Biochem 22: 713-719, 1985.[Impact factor 2.825; Cited 25]

Tilley WD, Horsfall D, Cant EL and Marshall VR. Specific binding of oestradiol to guinea pig prostate cytosol and nuclear fractions. J Steroid Biochem 22: 705-711, 1985. [Impact factor 2.825; Cited 11]

Tilley WD. Hormonal regulation of the prostate - the role of estrogen and its receptor (Ph.D. thesis), 1983.

Tilley WD. The endocrinology of the prostate - a review. Proc Endocr Soc Aust 26, Suppl 1, 1983. [no impact factor]

Tilley WD, Keightley DD and Marshall VR. Oestrogen and progesterone receptors in benign prostatic hyperplasia in humans. J Steroid Biochem 13: 395-399, 1980. [Impact factor 2.825; Cited 27]

Tilley WD, Keightley DD and Cant EL. Intersite variations of oestrogen receptors in human breast cancer. Brit J Cancer 38: 544-546, 1978. [Impact factor 4.459; Cited 41]

Keightley DD, Tilley WD and Cant EL. Effect of snap freezing dithiothreitol and storage on estimations of oestrogen receptor sites. Clin Chim Acta 88: 337-343, 1978. [Impact factor 2.328]

Track Record of Professor Wayne D. Tilley:

Professor Tilley returned to Australia in late 1990 after a NHMRC CJ Martin Fellowship at UT Southwestern in Dallas, Texas where he was one of the first to clone the human androgen receptor (AR). Since then, Prof Tilley’s laboratory has made a major contribution to understanding the molecular mechanisms of resistance to conventional hormonal (androgen ablation) therapies used in the treatment of prostate cancer. In particular, his laboratory has shown that continued signalling via the AR is an important determinant of disease progression and treatment response in metastatic prostate cancer. His laboratory has also pioneered research into understanding the regulation of breast cancer by androgens. A current major research focus is the development of new treatments for breast and prostate cancer based on AR signalling. In 1995, Prof Tilley co-published in PNAS with Prof Norman Greenberg (Baylor College of Medicine, Houston, TX) on the now widely used TRAMP mouse model of prostate cancer. Recently this collaboration resulted in development of an exciting new model of prostate cancer where prostate tumorigenesis occurs solely as a consequence of enforced expression of an AR variant in the mouse prostate (PNAS 102:1151-1156, 2005).

Prof Tilley has published more than 100 publications, and his research has been presented at various international meetings, including: American Association for Cancer Research (AACR) Special Conferences, on Prostate Cancer (Palm Springs CA, 1994; Naples, Florida, 2001); Keystone Symposium, Breast and Prostate Cancer (Taos NM, 1996); International Congress of Endocrinology (San Francisco CA, 1996; Sydney 2000); CaPCURE Third Annual Scientific Retreat (Lake Tahoe NV, 1996); Third International Symposium on Hormonal Carcinogenesis (Seattle WA, 1998); Gordon Conferences on Hormonal Carcinogenesis (Tilton NH, 1999: Meriden NH, 2003); Keystone Symposium on Androgen Action (Keystone, CO 2004); The Prostate Cancer Charitable Trust Forum (New York, 2004), The Prostate Cancer Foundation Annual Scientific Retreat (Lake Tahor, NV, 2004), the Keystone Breast and Prostate Cancer Symposium (Monterey, CA, 2005); Gordon Research Conference, Hormone Action and Development in Cancer, (Colby Sawyer College, NH, July 2007); US Endrocrine Society 89th Annual Meeting (Toronto, Canada, 2007).

Prof Tilley is a member of the Board of Andrology Australia (NHMRC Centre of Excellence in Male Reproductive Health); the National Breast Cancer Foundation, the Prostate Cancer Foundation of Australia and the NSW Cancer Institute Research Advisory Committees; the University of Adelaide Faculty of Health Sciences Research Grants Committee and the Executive of the Hanson Institute. Prof. Tilley was a Director of the Australian Society for Medical Research (1984-1987; 1991-1993), being President in 1993. In 1997, in conjunction with Professor Villis Marshall, he established the Australian Prostate Cancer Collaboration Inc (APCC), and in the same year was appointed Director of the Flinders Cancer Centre. Prof Tilley undertook a sabbatical in the Department of Preventive Medicine, the Norris Cancer Center, University of Southern California from October 2001 – May 2002. In 2002 Prof Tilley relocated to the University of Adelaide/Hanson Institute to take up the position of the Dame Roma Mitchell Chair in Cancer Research. Since that time, he has convened the Hanson Symposium at the ASMR National Scientific Conference in 2003, and was an organiser of the ASMR Conference for 2005, which is focused on Hormones, Fertility and Cancer. In 2003, he initiated and ran the Inaugural PacRim (Pacific Rim) Breast and Prostate Cancer Meeting, which attracted eminent scientists in the field from around the world to South Australia. The success of this meeting led to a Second PacRim Meeting being held in Palm Springs in April 2005 with a Third PacRim Meeting being organised by Prof Tilley at Fraser Island in November 2006.